We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

Traders around the word awaited U.S. inflation data for September—and the implications it will have for rate cuts at the ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

The FTSE 100 index closed down 6.01 points, 0.1%, at 8,237.73. The FTSE 250 ended 114.01 points lower, 0.6%, at 20,708.37, and the AIM All-Share fell 2.13 points, 0.3%, to 734.53.

GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...

Shares of the UK-based pharma giant GlaxoSmithKline PLC ($GB:GSK) soared over 6% after the company announced a settlement of ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

San Antonio attorney Mikal Watts is among a group of lawyers that negotiated a settlement of as much as $2.2 billion to resolve claims by about 80,000 people who allege a discontinued version of the ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle most of lawsuits filed in U.S.